Sanofi to acquire Translate Bio; advances deployment of mRNA
technology across vaccines and therapeutics development
Sanofi to acquire Translate
Bio;
advances
deployment of mRNA technology across vaccines and
therapeutics development
- Accelerates development of current Sanofi licensed programs in
vaccines and potential to explore other therapeutic areas
- Fast tracks establishment of Sanofi’s recently announced mRNA
Center of Excellence
- Full integration upgrades drug formulation capabilities and
enhances US talent in a promising new technology
PARIS and LEXINGTON,
Mass – August
3, 2021
– As part of Sanofi’s endeavor to accelerate the
application of messenger RNA (mRNA) to develop therapeutics and
vaccines, the company has entered into a definitive agreement with
Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics
company, under which Sanofi will acquire all outstanding shares of
Translate Bio for $38.00 per share in cash, which represents a
total equity value of approximately $3.2 billion (on a fully
diluted basis). The Sanofi and Translate Bio Boards of Directors
unanimously approved the transaction.
“Translate Bio adds an mRNA technology platform
and strong capabilities to our research, further advancing our
ability to explore the promise of this technology to develop both
best-in-class vaccines and therapeutics,” said Paul Hudson, Sanofi
Chief Executive Officer. “A fully owned platform allows us to
develop additional opportunities in the fast-evolving mRNA space.
We will also be able to accelerate our existing partnered programs
already under development. Our goal is to unlock the potential of
mRNA in other strategic areas such as immunology, oncology, and
rare diseases in addition to vaccines.”
“Sanofi and Translate Bio have a shared
commitment to innovation in the mRNA space. With Sanofi’s
long-standing expertise in developing and commercializing vaccines
and other innovative medicines on a global scale, Translate Bio’s
mRNA technology is now even better positioned to reach more people,
faster,” said Ronald Renaud, Chief Executive Officer, Translate
Bio. “The talented and dedicated Translate Bio team has built the
foundation of a strong mRNA platform. Our expertise coupled with
that of Sanofi has driven significant progress under the
collaboration thus far, and we believe that this acquisition will
strengthen the team’s ability to achieve the full potential of the
mRNA technology.”
In June 2018, Sanofi and Translate Bio entered
into a collaboration and exclusive license agreement to develop
mRNA vaccines which was further expanded in 2020 to broadly address
current and future infectious diseases. There are two ongoing mRNA
vaccine clinical trials under the collaboration, the COVID-19
vaccine Phase 1/2 study with results expected in Q3 2021 and the
mRNA seasonal influenza vaccine Phase 1 trial with results due in
Q4 2021. The acquisition builds on Sanofi’s establishment of a
first-of-its kind vaccines mRNA Center of Excellence.
On the therapeutic side, Translate Bio has an
early-stage pipeline in cystic fibrosis and other rare pulmonary
diseases. In addition, discovery work is ongoing in diseases that
affect the liver, and Translate Bio’s MRTTM platform may be applied
to various classes of treatments, such as therapeutic antibodies or
vaccines in areas such as oncology. Sanofi’s recent acquisition of
Tidal Therapeutics expanded the company’s mRNA research
capabilities in both immuno-oncology and inflammatory diseases. The
Translate Bio acquisition further accelerates Sanofi’s efforts to
develop transformative medicines using mRNA technology.
Transaction Terms
Under the terms of the merger agreement, Sanofi
will commence a cash tender offer to acquire all outstanding shares
of Translate Bio common stock for $38.00 per share in cash
reflecting a total equity value of Translate Bio of approximately
$3.2 billion. The purchase price represents a premium of 56% to
Translate Bio’s volume-weighted average price per share over the
past 60 days.
To demonstrate their commitment to the
transaction, the chief executive officer of Translate Bio and
Translate Bio’s largest shareholder, The Baupost Group, L.L.C.,
have signed binding commitments to support the tender offer. These
binding commitments, combined with the Translate Bio shares already
owned by Sanofi or its affiliates, represent a total of
approximately 30% of Translate Bio’s total shares outstanding.
The consummation of the tender offer is subject
to customary closing conditions, including the tender of a number
of shares of Translate Bio common stock that together with shares
already owned by Sanofi or its affiliates represents at least a
majority of the outstanding shares of Translate Bio common stock,
the expiration or termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other
customary conditions. Following the successful completion of the
tender offer, a wholly owned subsidiary of Sanofi will merge with
Translate Bio and the outstanding Translate Bio shares not already
owned by Sanofi or its affiliates that are not tendered in the
tender offer will be converted into the right to receive the same
$38.00 per share in cash paid in the tender offer. The tender offer
is expected to commence later this month. Sanofi plans to fund the
transaction with available cash resources. Subject to the
satisfaction or waiver of customary closing conditions, Sanofi
expects to complete the acquisition in the third quarter of
2021.
Morgan Stanley & Co. International plc is
acting as exclusive financial advisor to Sanofi while Weil, Gotshal
& Manges LLP is acting as legal counsel. Centerview Partners is
acting as lead financial advisor to Translate Bio in the
transaction, while Paul, Weiss, Rifkind, Wharton & Garrison LLP
is acting as legal counsel. Evercore is also acting as a financial
advisor in this transaction to Translate Bio. MTS Health Partners,
LP is also giving financial advice to Translate Bio.
About Translate
Bio
Translate Bio is a clinical-stage mRNA
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, or to prevent infectious diseases by generating
protective immunity. Translate Bio is primarily focused on applying
its technology to treat pulmonary diseases with a lead pulmonary
candidate being evaluated as an inhaled treatment for cystic
fibrosis in a Phase 1/2 clinical trial. Additional pulmonary
diseases are being evaluated in discovery-stage research programs
that utilize a proprietary lung delivery platform. Translate Bio
also believes it technology may apply broadly to a wide range of
diseases, including diseases that affect the liver. Additionally,
the platform may be applied to various classes of treatments, such
as therapeutic antibodies and protein degradation. Translate Bio is
also pursuing the development of mRNA vaccines for infectious
diseases under a collaboration with Sanofi
Pasteur. About
Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare diseases and the millions with
long-term chronic conditions.
With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe.
Sanofi Media Relations
Contacts Ashleigh
Koss Tel: +1 (908)
205-2572 Ashleigh.Koss@sanofi.com
Sandrine
Guendoul Tel.: +33
(0)6 25 09 14
25 Sandrine.Guendoul@sanofi.com
Sanofi Investor
Relations Contacts ParisEva Schaefer-JansenArnaud
DelepineNathalie Pham
Sanofi Investor Relations Contacts
North AmericaFelix LauscherFara BerkowitzSuzanne Greco
Tel.: +33 (0)1 53 77 45
45 investor.relations@sanofi.com
https://www.sanofi.com/en/investors/contact
Translate Bio Media Relations
ContactMaura Gavaghanmgavaghan@translate.bio
Translate Bio Investor Relations
ContactTeri Dahlmantdahlman@translate.bio
Sanofi and Translate
Bio Forward-Looking Statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts and may include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans”, “will be” and similar expressions. Although
Sanofi’s and Translate Bio ’s management each believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi and Translate Bio, that could cause
actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, risks related to Sanofi’s and Translate Bio’s
ability to complete the acquisition on the proposed terms or on the
proposed timeline, including the receipt of required regulatory
approvals, the possibility that competing offers will be made,
other risks associated with executing business combination
transactions, such as the risk that the businesses will not be
integrated successfully, that such integration may be more
difficult, time-consuming or costly than expected or that the
expected benefits of the acquisition will not be realized, risks
related to future opportunities and plans for the combined company,
including uncertainty of the expected financial performance and
results of the combined company following completion of the
proposed acquisition, disruption from the proposed acquisition
making it more difficult to conduct business as usual or to
maintain relationships with customers, employees, manufacturers,
suppliers or patient groups, and the possibility that, if the
combined company does not achieve the perceived benefits of the
proposed acquisition as rapidly or to the extent anticipated by
financial analysts or investors, the market price of Sanofi’s
shares could decline, as well as other risks related Sanofi’s and
Translate Bio’s respective businesses, including the ability to
grow sales and revenues from existing products and to develop,
commercialize or market new products, competition, the
uncertainties inherent in research and development, including
future clinical data and analysis, regulatory obligations and
oversight by regulatory authorities, such as the FDA or the EMA,
including decisions of such authorities regarding whether and when
to approve any drug, device or biological application that may be
filed for any product candidates as well as decisions regarding
labelling and other matters that could affect the availability or
commercial potential of any product candidates, the absence of a
guarantee that any product candidates, if approved, will be
commercially successful, the future approval and commercial success
of therapeutic alternatives, Sanofi’s ability to benefit from
external growth opportunities and to complete related transactions
and/or obtain regulatory clearances, risks associated with Sanofi’s
and Translate Bio’s intellectual property and any related pending
or future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on Sanofi and Translate Bio and their respective customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on Sanofi’s and Translate
Bio’s employees and on the global economy as a whole. Any material
effect of COVID-19 on any of the foregoing could also adversely
impact Sanofi and Translate Bio. This situation is changing rapidly
and additional impacts may arise of which Sanofi and Translate Bio
are not currently aware and may exacerbate other previously
identified risks. While the list of factors presented here is
representative, no list should be considered a statement of all
potential risks, uncertainties or assumptions that could have a
material adverse effect on companies’ consolidated financial
condition or results of operations. The foregoing factors should be
read in conjunction with the risks and cautionary statements
discussed or identified in the public filings with the U.S.
Securities and Exchange Commission (the “SEC”) made by Sanofi and
Translate Bio and the public filings with the AMF made by Sanofi,
including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020, and
Translate Bio’s annual report on Form 10-K for the year ended
December 31, 2020, quarterly reports on Form 10-Q and current
reports on Form 8-K filed with the SEC. The forward-looking
statements speak only as of the date hereof and, other than as
required by applicable law, Sanofi and Translate Bio do not
undertake any obligation to update or revise any forward-looking
information or statements.
Additional Information for US
shareholders
The tender offer for the outstanding shares of
Translate Bio common stock referenced in this press release has not
yet commenced. This press release is for informational purposes
only and is neither an offer to purchase nor a solicitation of an
offer to sell securities, nor is it a substitute for the tender
offer materials that Sanofi and its acquisition subsidiary will
file with the SEC, upon the commencement of the tender offer. At
the time the tender offer is commenced, Sanofi and its acquisition
subsidiary will file a tender offer statement on Schedule TO and
thereafter Translate Bio will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the tender
offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE,
A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER
DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON
SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. TRANSLATE BIO
STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY
BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME
TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT
HOLDERS OF TRANSLATE BIO SECURITIES SHOULD CONSIDER BEFORE MAKING
ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to
Purchase, the related Letter of Transmittal and certain other
tender offer documents, as well as the Solicitation/Recommendation
Statement, will be made available to all holders of Translate Bio
stock at no expense to them. The tender offer materials and the
Solicitation/Recommendation Statement will be made available for
free at the SEC’s website at www.sec.gov. Additional copies may be
obtained for free by contacting Sanofi or Translate Bio. Copies of
the documents filed with the SEC by Translate Bio will be available
free of charge on Translate Bio’s internet website at
www.translate.bio or by contacting Translate Bio’s Investor
Relations Department at tdahlman@translate.bio. Copies of the
documents filed with the SEC by Sanofi will be available free of
charge on Sanofi’s internet website at
https://www.sanofi.com/en/investors or by contacting Sanofi’s
Investor Relations Department at investor.relations@sanofi.com.
In addition to the Offer to Purchase, the
related Letter of Transmittal and certain other tender offer
documents, as well as the Solicitation/Recommendation Statement,
Sanofi files annual and special reports and other information with
the SEC and Translate Bio files annual, quarterly and special
reports and other information with the SEC. You may read and copy
any reports or other information filed by Sanofi and Translate Bio
at the SEC public reference room at 100 F. Street, N.E., Washington
D.C. 20549. Please call the Commission at 1-800-SEC-0330 for
further information on the public reference room. Sanofi’s and
Translate Bio’s filings with the SEC are also available to the
public from commercial document-retrieval services and at the
website maintained by the SEC at www.sec.gov.
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024